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Background: Raltegravir 1200mg (2·600mg tablets) once daily
(QD) demonstrated noninferior efficacy and similar safety to
raltegravir 400mg twice daily (BID) at week 48 of the ONCEMRK
trial. Here, we report the week 96 results from this study.
Methods: ONCEMRK is a phase 3, multicenter, double-blind,
noninferiority trial comparing raltegravir 1200mg QD with ralte-
gravir 400mg BID in treatment-naive HIV-1–infected adults. Par-
ticipants were assigned (2:1) to raltegravir 2·600mg QD or 400mg
BID, both with emtricitabine and tenofovir disoproxil fumarate
(FTC/TDF) for 96 weeks. Randomization was stratified by screening
HIV-1 RNA and hepatitis B/C status. Efficacy was assessed as the
proportion of participants with HIV-1 RNA ,40 copies per milliliter
(Food and Drug Administration Snapshot approach); the noninfer-
iority margin was 10 percentage points.
Results: Of the 797 participants who received study therapy (84.6%
were men, 59.3% were white, and mean age was 35.9 years), 694
completed 96 weeks of treatment (87.6% QD; 84.4% BID), with few
discontinuations because of lack of efficacy (1.1% for both groups)
or adverse events (1.3% QD; 2.3% BID). At week 96, 81.5% (433/
531) of QD recipients and 80.1% (213/266) of BID recipients
achieved HIV-1 RNA ,40 copies per milliliter (difference 1.4%,
95% confidence interval: 24.4 to 7.3). CD4+ T-cell counts increased
.260 cells/mm3 from baseline in both groups. Resistance to
raltegravir was infrequent, occurring in 0.8% of each treatment
group through week 96. Adverse event rates were similar for the
2 regimens.
Conclusions: In HIV-1–infected treatment-naive adults receiving
FTC/TDF, raltegravir 1200mg QD demonstrated noninferior efficacy
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to raltegravir 400mg BID that was durable to week 96, with a safety
profile similar to raltegravir 400mg BID.
Key Words: raltegravir, once daily, integrase inhibitor, HIV-1
infection, treatment-naive
(J Acquir Immune Defic Syndr 2018;78:589–598)
INTRODUCTION
Raltegravir 400 mg twice daily (BID), the first integrase
strand transfer inhibitor (INSTI) approved for the treatment of
HIV-1 infection, has a well-established safety and efficacy
profile in treatment-naive and treatment-experienced pa-
tients.1–4 A once-daily formulation of raltegravir 1200 mg
(2 · 600 mg tablets) has been developed and has the potential
to improve treatment adherence and satisfy patient preference
for a once-daily regimen.5–8 This new formulation is
approved for use in combination with other antiretroviral
agents for previously untreated HIV-1 infection in adults and
in children weighing $40 kg.9 In the ONCEMRK phase 3
trial, raltegravir 1200 mg once daily (QD) showed noninferior
efficacy to raltegravir 400 mg BID, with 88.9% and 88.3% of
participants, respectively, achieving HIV-1 RNA ,40 copies
per milliliter at week 48.10 In addition, the immunologic
efficacy and overall safety profile of raltegravir QD were
similar to those of raltegravir BID at week 48. Here, we report
the long-term efficacy and safety of raltegravir 1200 mg QD




ONCEMRK (MK-0518 Protocol 292; ClinicalTrials.
gov NCT02131233) was a double-blind, randomized, parallel
group, noninferiority study comparing raltegravir 1200 mg
QD with raltegravir 400 mg BID, each given with a fixed
combination of emtricitabine 200 mg and tenofovir disoproxil
fumarate 300 mg (FTC/TDF). The study was conducted
according to Good Clinical Practice requirements and appli-
cable statutes and regulations regarding the protection of
human participants in biomedical research. An Independent
Ethics Committee for each study site reviewed and approved
the protocol, and the participants provided written informed
consent before any study procedures were performed.
Adults ($18 years of age) with screening HIV-1 RNA
$1000 copies per milliliter and no previous antiretroviral
therapy for treatment of HIV-1 infection were eligible for the
study. Exclusion criteria included documented or known
resistance to any of the study regimen components and acute
hepatitis or active infections other than chronic hepatitis B or
C infection. Participants were randomly assigned (2:1) to
raltegravir 1200 mg QD or 400 mg BID, each in combination
with open-label FTC/TDF (TRUVADA; Gilead Sciences,
Inc., Carrigtohill, County Cork, Ireland) for up to 96 weeks.
Randomization was stratified by screening HIV-1 RNA
(#100,000 or .100,000 copies per milliliter) and hepatitis
B/C coinfection (yes or no). To conceal the treatment group
assignment, participants also received placebo tablets match-
ing the alternate treatment. Participants, study site investi-
gators and staff, and sponsor personnel responsible for
monitoring the study remained unaware of the treatment
group assignments until the week 96 database lock.
Procedures
Plasma HIV-1 RNA levels were measured by the
central laboratory using the Abbott RealTime HIV-1 Assay
(lower limit of quantification 40 copies per milliliter).
Protocol-defined virologic failure (PDVF) was used to
identify participants for viral resistance testing. PDVF con-
sisted of nonresponse (participant did not achieve HIV-1
RNA ,40 copies per milliliter by week 24) or rebound (after
initial response of HIV-1 RNA ,40 copies per millliliter,
participant had 2 consecutive measurements of HIV-1 RNA
$40 copies per milliliter at least 1 week apart). Resistance
testing was performed by Monogram Biosciences Inc. using
the following assays: PhenoSense GT, PhenoSense Integrase,
and either GeneSeq Integrase or GenoSure Integrase; all
assays required samples with HIV-1 RNA $500 copies
per milliliter.
CD4+ T-cell counts were measured at weeks 24, 48, 72,
and 96 by the central laboratory according to standard
procedures. All clinical adverse events were evaluated for
maximum intensity, seriousness, relationship to test drugs,
and association with immune reconstitution syndrome. All
protocol-required laboratory values were graded according to
the Division of AIDS criteria.11
Participants completed a daily medication diary that
was reviewed by site personnel at each study visit. A day
within the study was counted as “on therapy” if at least 1
tablet of any study medication was taken. Treatment compli-
ance was calculated from the number of days on therapy as
recorded in the medication diary (actual/planned · 100). For
participants who were compliant with therapy but had HIV-1
RNA .200 copies per milliliter (on 2 consecutive measure-
ments taken at least 1 week apart) on or after week 24 or after
previously achieving HIV-1 RNA ,40 copies per milliliter,
the protocol recommended that discontinuation of study
therapy should be considered by the study investigator.
Statistical Analysis
The primary efficacy end point for this trial was
assessed at week 48 and has been previously reported.10 This
report presents additional data to evaluate the secondary
hypothesis that raltegravir 1200 mg QD is noninferior to
raltegravir 400 mg BID, each in combination with TDF/FTC,
as assessed by the proportion of participants achieving HIV-1
RNA ,40 copies per milliliter at week 96. A margin of 10
percentage points was used to assess noninferiority. The week
96 hypothesis was tested sequentially after the week 48
hypothesis was successfully met; therefore, the overall type I
error was controlled at one-sided 2.5% alpha level.
The efficacy analyses used the Full Analysis Set
population, defined as all randomized participants who
received at least 1 dose of study treatment, with participants
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included in the treatment group to which they were random-
ized. SAS version 9.3 or 9.4 was used for all analyses.
For the analysis of the proportion of participants with
HIV-1 RNA ,40 copies per milliliter, all missing data were
treated as failures regardless of the reason, including early
discontinuation of study therapy (Food and Drug Adminis-
tration snapshot approach). The difference in proportions
between treatment groups and the associated 95% confidence
FIGURE 1. Disposition of study participants.
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interval (CI) were calculated by the stratum-adjusted Mantel-
Haenszel method. A supportive analysis of the proportion of
participants with HIV-1 RNA ,50 copies per milliliter was
also performed using the methods described above.
For the analysis of change from baseline in CD4+ T-cell
counts, missing data were handled with the Observed Failure (OF)
approach. Baseline values were carried forward for participants
who discontinued the assigned therapy because of lack of efficacy
and for those who discontinued for non–treatment-related reasons
and had HIV-1 RNA $40 copies per milliliter; participants with
missing data for other reasons were excluded.
To evaluate the consistency of treatment effects, the
virologic and immunologic end points were estimated within
subgroups based on a variety of prognostic and demographic
factors using the OF approach (see above); no hypothesis
testing was performed within or between subgroups. The OF
approach was used because it focuses on the impact of the
antiretroviral treatment, whereas the snapshot approach consid-
ers the impact of treatment and non–treatment-related factors.
The safety analyses used the all-participants-as-treated
population, which consists of all randomized participants who
received at least 1 dose of study treatment and includes
participants in the treatment group for the regimen they actually
received. Adverse events that occurred after randomization and
were reported through the week 96 window were included in the
analyses. Adverse event terms from the Medical Dictionary for
Regulatory Activities (Version 18.1) were used. For laboratory
changes occurring in$1% of the participants in either treatment
group, between-treatment differences (and 95% CI) were
calculated using the Miettinen and Nurminen method.12
RESULTS
Of the 802 randomized participants, 797 received study
therapy and were included in the efficacy and safety analyses.
Baseline characteristics of the participants were similar
between the treatment groups (see Table, Supplemental
Digital Content 1, http://links.lww.com/QAI/B166). Mean
age of the study population was 35.9 years, and 85% of the
participants were men. Mean HIV-1 RNA was 4.6 log10
copies per milliliter, and 28% of participants had .100,000






Primary endpoint (NC = F)
HIV-1 RNA ,40 copies/mL 433 (81.5) 213 (80.1)
HIV-1 RNA$40 copies/mL* 49 (9.2) 22 (8.3)
No virologic data at week 96
window
49 (9.2) 31 (11.7)
Discontinued study
because of AE or death
7 (1.3) 7 (2.6)
Discontinued study for
other reasons†
36 (6.8) 20 (7.5)
On study therapy but
missing data in window
6 (1.1) 4 (1.5)
Supportive endpoints
,40 copies/mL (OF) 433/482 (89.8) 213/235 (90.6)
,50 copies/mL (NC=F) 439/531 (82.7) 215/266 (80.8)
,50 copies/mL (OF) 439/482 (91.1) 215/235 (91.5)
Raltegravir 1200 mg QD and 400 mg BID were administered with FTC/TDF.
*Includes participants who changed any component of background therapy to a new
drug class, to components not permitted per protocol, or because of lack of efficacy
before week 96; participants who discontinued before week 96 because of lack or loss of
efficacy; and participants with HIV-1 RNA $40 copies per milliliter in the week 96
window (relative day 631–714).
†Other reasons include the following: lost to follow-up, noncompliance with the
study drug, physician decision, pregnancy, and withdrawal by the subject.
OF, Observed Failure approach; NC=F, Non-Completer equals Failure approach (as
defined by FDA snapshot algorithm).
FIGURE 2. Proportion of participants with HIV-
1 RNA ,40 copies per milliliterover time, Food
and Drug Administration snapshot approach.
Raltegravir (RAL) 1200 mg QD and 400 mg BID
were given with TDF/FTC.
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copies per milliliter; mean CD4+ T-cell count was 415/mm3
and 13% had ,200/mm3. A total of 64 participants (12.0%)
from the raltegravir QD group and 39 (14.5%) from the
raltegravir BID group discontinued early without completing
the study. The most common reasons for discontinuation were
lost to follow-up and withdrawal by the subject (Fig.1).
FIGURE 3. Efficacy of raltegravir 1200 mg QD and raltegravir 400 mg BID by baseline prognostic and demographic factors
(Observed Failure approach).
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Treatment compliance was high overall: 97.2% of QD
recipients and 95.9% of BID recipients were at least 90%
compliant with study therapy.
Efficacy
At week 96, HIV-1 RNA ,40 copies per milliliter was
achieved by 81.5% (433/531) of the participants who received
raltegravir 1200 mg QD and by 80.1% (213/266) of those
who received raltegravir 400 mg BID (Fig.2). The treatment
difference was 1.4%, with an associated 95% CI of 24.4 to
7.3, demonstrating noninferiority of raltegravir 1200 mg QD
to raltegravir 400 mg BID. Other virologic outcomes were
comparable between the treatment groups: 9.2% of the QD
group and 8.3% of the BID group had HIV-1 RNA $40
copies per milliliter, whereas 9.2% and 11.7%, respectively,
had no virologic data at week 96 (Table 1).
Similar efficacy also was demonstrated between raltegra-
vir QD and raltegravir BID on the supportive endpoint of
virologic response defined as HIV-1 RNA ,50 copies per
milliliter (82.7% vs 80.8%). The mean change from baseline in
CD4+ T-cell count was 262 cells/mm3 in both treatment groups,
with a treatment difference (95% CI) of 20.6 (232.8 to 31.6).
In the subgroup analyses, raltegravir 1200 mg QD
showed durable antiretroviral and immunologic efficacy
comparable to that observed with raltegravir 400 mg BID,
regardless of prognostic and demographic factors (Fig.3).
Participants with high baseline viral load (.100,000 copies
per milliliter) showed similar robust virologic responses at
week 96 in both the QD and BID treatment groups (HIV-1
RNA ,40 copies per milliliter achieved in 84.7% and 82.9%,
respectively), as well as similar increases in CD4+ T-cell
counts (297 and 281 cells/mm3, respectively).
By week 96, a total of 77 participants met the PDVF
criteria for nonresponse or rebound, 9.6% (51/531) of the
raltegravir QD group and 9.8% (26/266) of the raltegravir BID
group, with 23 cases (15 QD; 8 BID) occurring after week 48.
Most (92.2%) participants with PDVF were at least 90%
compliant with study therapy. A substantial number of participants
who met the PDVF criteria remained on study therapy (at the
investigator’s discretion, as allowed by the protocol) and achieved
HIV-1 RNA,40 copies per milliliter at week 96: 45.1% (23/51)
in the QD group and 57.7% (15/26) in the BID group.
Most participants with PDVF had low-level viremia,
and only 25 (17 QD, 8 BID) could be tested for viral drug
TABLE 2. Protocol-Defined Virologic Failure and Resistance
Testing
RAL 1200 mgQD +
TDF/FTC (N=531)
RAL 400 mg BID
+ TDF/FTC
(N=266)
Participants with PDVF* 51 (9.6) 26 (9.8)




2180 (54–151,154) 1234 (,40 to
228,213)
Time (wk) between Failure
and resistance testing,
median (range)‡
12 (0–70) 7 (0–57)
Resistance test results
No known RAL resistance
mutations
9 (1.7) 3 (1.1)
Failed integrase
amplification
4 (0.8) 3 (1.1)
RAL resistance mutations
detected







2: N155H; M184M/I/V 2: N155H, I203M,
L74I; D67D/N,
M184V










,100,000 1/382 (0.3) 0/189 (0.0)
100,000–500,000 1/124 (0.8) 1/62 (1.6)
.500,000 2/25 (8.0) 1/15 (6.7)
CD4+ T-cell count (cells/
mm3)
.200 0/462 (0.0) 0/229 (0.0)
50 to 200 2/60 (3.3) 2/31 (6.5)
,50 2/9 (22.2) 0/6 (0.0)
*PDVF: nonresponse (did not achieve HIV-1 RNA ,40 copies per milliliter by
week 24) or rebound (HIV-1 RNA $40 copies per milliliter after initial response of
HIV-1 RNA ,40 copies per milliliter and confirmed at least 1 week later).
†Resistance testing required blood sample with HIV-1 RNA at least 500 copies per
milliliter (threshold of the assay).
‡Time of resistance testing was affected by availability of a sample with sufficient
HIV-1 RNA.
TABLE 3. Summary of Clinical Adverse Events, Cumulative
Rates Through Week 48 and Week 96
No. (%) of Participants









One or more AE 439 (82.7) 231 (86.8) 479 (90.2) 248 (93.2)
Drug-related AE 130 (24.5) 68 (25.6) 138 (26.0) 71 (26.7)
Serious AE 31 (5.8) 25 (9.4) 49 (9.2) 42 (15.8)
Drug-related serious
AE
1 (0.2) 2 (0.8) 1 (0.2) 2 (0.8)
Discontinued study
because of AE
4 (0.8) 6 (2.3) 5 (0.9) 6 (2.3)
Because of drug-
related AE








0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Deaths† 2 (0.4) 1 (0.4) 2 (0.4) 1 (0.4)
*In combination with FTC/TDF once daily.
†Two deaths in RAL 1200 mg QD arm: immunoblastic lymphoma and TB; 1death
in RAL 400 mg BID arm: AIDS (multiple opportunistic infections). No deaths occurred
after week 48.
Cahn et al J Acquir Immune Defic Syndr  Volume 78, Number 5, August 15, 2018
594 | www.jaids.com Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
resistance because of the assay threshold of HIV-1 RNA
$500 copies per milliliter (Table 2). Viral resistance to INSTI
and nucleoside reverse transcriptase inhibitor (NRTI)
occurred in 0.8% of each treatment group (4/531 QD, 2/266
BID), and NRTI resistance alone occurred in 0.4% of each
group (2/531 QD; 1/266 BID). The profile of INSTI
resistance mutations included integrase N155H, V151I,
L74M, E92Q, and I203M. Five of the 6 participants who
developed resistance to raltegravir had baseline HIV-1 RNA
.100,000 copies per milliliter (3 had .500,000 copies per
milliliter), and all 6 had baseline CD4+ T-cell counts ,200/
mm3 (2 had ,50/mm3). Self-reported treatment adherence
was high in all 6 of these participants (95%–100% in the QD
group; 91%–100% in the BID group).
Safety
Rates of clinical adverse events were similar between the
treatment groups at week 96 and showed minimal change from
week 48 to week 96 in both the treatment groups (Table 3).
Clinical adverse events led to treatment discontinuation by
week 96 in 0.9% of raltegravir QD recipients and 2.3% of
raltegravir BID recipients. Only 1 participant (who was in the
QD group) discontinued because of a clinical adverse event
(facial bone fracture) after week 48; this event was serious and
not related to study therapy. No deaths or drug-related serious
adverse events occurred after week 48. One participant in the
QD group had an adverse event (autoimmune hepatitis) after
week 48, which was considered by the investigator to be
associated with immune reconstitution inflammatory syn-
drome; this event was also considered to be related to study
therapy. The frequencies of other drug-related adverse events in
the QD group were unchanged between week 48 and week 96.
Drug-related nervous system adverse events occurred
in 37 (7.0%) of raltegravir QD recipients and 26 (9.8%) of
raltegravir BID recipients. Specific drug-related nervous
system adverse events with .2% incidence were dizziness
(2.3% vs 3.4%) and headache (3.0% vs 4.9%). Drug-related
psychiatric adverse events occurred in 21 (4.0%) of the QD
group and 12 (4.5%) of the BID group; specific drug-related
TABLE 4. Laboratory Changes Grade 2 or Higher, Incidence $1% in Either Treatment Group, Week 96
RAL 1200 mg QD* RAL 400 mg BID* Difference (QD 2 BID)
n/N (%) n/N (%) % (95% CI)
Neutrophils (103/mL)
Grade 2 (0.75–0.999) 8/530 (1.5) 2/265 (0.8) 0.8 (21.3 to 2.3)
Grade 3 (0.50–0.749) 7/530 (1.3) 3/265 (1.1) 0.2 (22.0 to 1.8)
Grades 2–4 combined 16/530 (3.0) 5/265 (1.9) 1.1 (21.5 to 3.3)
Platelets (103/mL)
Grade 2 (50–99.999) 6/529 (1.1) 1/266 (0.4) 0.8 (21.0 to 2.1)
Total bilirubin (mg/dL)
Grade 2 (1.6 2 2.5 ·ULN) 15/530 (2.8) 4/266 (1.5) 1.3 (21.2 to 3.4)
Aspartate aminotransferase (IU/L)
Grade 2 (2.6 2 5.0 ·ULN) 24/530 (4.5) 7/266 (2.6) 1.9 (21.1 to 4.5)
Grade 3 (5.1 2 10.0 ·ULN) 11/530 (2.1) 1/266 (0.4) 1.7 (20.1 to 3.4)
Grades 2–4 combined 38/530 (7.2) 9/266 (3.4) 3.8 (0.4 to 6.8)
Alanine aminotransferase (IU/L)
Grade 2 (2.6 2 5.0 ·ULN) 22/530 (4.2) 4/266 (1.5) 2.6 (0.0 to 5.0)
Grade 3 (5.1 2 10.0 ·ULN) 6/530† (1.1) 1/266 (0.4) 0.8 (21.0 to 2.1)
Grade 4 (.10.0 ·ULN) 6/530‡ (1.1) 1/266§ (0.4) 0.8 (21.0 to 2.1)
Grades 2–4 combined 34/530 (6.4) 6/266 (2.3) 4.2 (1.1 to 6.9)
Alkaline phosphatase
Grade 2 (2.6 2 5.0 ·ULN) 6/530 (1.1) 0/266 (0.0) 1.1 (20.3 to 2.4)
Lipase (IU/L)
Grade 2 (1.6 2 3.0 ·ULN) 37/530 (7.0) 14/266 (5.3) 1.7 (22.1 to 5.0)
Grade 3 (3.1 2 5.0 ·ULN) 8/530 (1.5) 2/266 (0.8) 0.8 (21.3 to 2.3)
Grade 4 (.5.0 ·ULN) 9/530 (1.7) 2/266 (0.8) 0.9 (21.1 to 2.6)
Grades 2–4 combined 54/530 (10.2) 18/266 (6.8) 3.4 (20.9 to 7.2)
Creatine phosphokinase (IU/L)
Grade 2 (6.0 2 9.9 ·ULN) 23/530 (4.3) 13/266 (4.9) 20.5 (24.1 to 2.4)
Grade 3 (10.02 19.9 ·ULN) 17/530 (3.2) 7/266 (2.6) 0.6 (22.4 to 2.9)
Grade 4 ($20.0 X ULN) 18/530 (3.4) 5/266 (1.9) 1.5 (21.2 to 3.8)
Grades 2–4 combined 58/530 (10.9) 25/266 (9.4) 1.5 (23.2 to 5.8)
*In combination with FTC/TDF once daily.
†One case was associated with acute hepatitis of undetermined etiology.
‡Two cases were associated with acute HCV infection and 1with acute HBV infection.
§This case was associated with acute HCV infection.
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psychiatric AEs occurred in less than 2% of the participants
in each treatment group.
Laboratory abnormalities above grade 1 by the Division
of AIDS criteria were uncommon and occurred at similar
rates in the raltegravir QD and BID groups (Table 4) with 1
exception: grade 2 elevations of alanine aminotransferase
(ALT) occurred in 4.2% of the QD group vs 1.5% of the BID
group; however, these elevations were generally transient, not
associated with clinical adverse events, and not considered
clinically significant by the investigators.
Grade 3 or 4 ALT elevations occurred in 12 (2.3%)
participants in the QD group and 2 (0.8%) in the BID group
by week 96; about half of these events (5 and 1, respectively)
occurred after week 48. Most of these events were related to
concurrent conditions (hepatitis in 8 participants, hepatocel-
lular injury in 1, hepatic steatosis in 1, and isoniazid treatment
in 1). The 3 cases with no obvious etiology resolved on study
therapy. Grade 3 or 4 elevations in creatine phosphokinase
(CPK) occurred in 35 (6.6%) QD recipients and 12 (4.5%)
BID recipients by week 96; of these, 19 and 1, respectively,
occurred after week 48. These changes were transient and
resolved on therapy in most cases (33 and 11, respectively).
Grade 3 or 4 lipase elevations occurred in 17 (3.2%) of the
QD group and 4 (1.6%) of the BID group by week 96; of
these, 4 and 3, respectively, occurred after week 48. Lipase
elevations were not associated with clinical symptoms with
the exception of 1 QD recipient who experienced moderate
pancreatitis that resolved while continuing study therapy.
Two participants (both in the QD group) discontinued
therapy because of laboratory changes: increased ALT and
aspartate aminotransferase (AST) (grade 3 and 1, respec-
tively) in 1 and increased CPK (grade 4) in the other; both
events occurred before week 48. None of the laboratory
events that occurred after week 48 led to treatment discon-
tinuation in either treatment group.
Two participants met the criteria for potential drug-
induced liver injury (AST or ALT $3xULN [upper limit of
the normal range] with bilirubin $2xULN and alkaline
phosphatase ,2xULN): 1 in the QD group before week 48
and 1 in the BID group after week 48. In both cases, there
were alternative explanations for the laboratory findings
(hepatitis B virus flare and acute hepatitis C
virus, respectively).
Among participants with hepatitis coinfection, no drug-
related adverse events, serious adverse events, or discontin-
uations because of adverse events were reported after week 48
in either treatment group. Two of the 15 coinfected partic-
ipants in the raltegravir QD group had laboratory adverse
events after week 48 (grade 4 elevations of lipase and creatine
kinase, respectively), but neither event was considered
drug-related. No new reports of AST or ALT elevations
above grade 2 occurred after week 48 among coinfected
participants in either treatment group.
DISCUSSION
The final 96-week results of this pivotal phase 3 trial in
treatment-naive adults with HIV-1 infection demonstrate the
durable and noninferior efficacy of raltegravir 1200 mg QD
compared with raltegravir 400 mg BID, each in combination
with FTC/TDF. The noninferior efficacy and favorable safety
profile of raltegravir 1200 mg QD were first demonstrated at
week 48 and have been previously reported.10 At week 96,
the efficacy of raltegravir 1200 mg QD was again shown to be
noninferior to that of raltegravir 400 mg BID, as assessed by
the proportion of participants with HIV-1 RNA ,40 copies
per milliliter. Similar results were observed for the supportive
virologic endpoint of HIV-1 RNA ,50 copies per milliliter,
and both treatment groups continued to show substantial
increases in CD4+ T-cell counts (over 260 cells/mm3) through
week 96. In addition, raltegravir 1200 mg QD showed
comparable efficacy to raltegravir 400 mg BID across all
subgroups examined, including those with high baseline viral
load. Overall, the efficacy of raltegravir 1200 mg QD in this
study is comparable to that of dolutegravir and elvitegravir
reported at 96 weeks.13–18
PDVF was used to identify participants for drug
resistance testing. At week 96, the frequency of PDVF was
low and similar between the raltegravir QD and BID groups
(9.6% and 9.8%, respectively). The rate of viral drug
resistance also remained low, with only 3 additional reports
after week 48: 1 in the QD group and 2 in the BID group. By
week 96, 0.8% of each group developed resistance to INSTI
and resistance to NRTI. Development of resistance was
associated with high baseline viral load and low CD4+ T-
cell count in 5 of the 6 cases, but did not seem to be related to
poor treatment adherence. In previous studies of raltegravir
400 mg BID in treatment-naive adults, rates of resistance to
INSTI ranged from 1% to 2% at 96 weeks of follow-up.19,20
The specific integrase mutations observed in this study were
consistent with those found in the Phase 3 studies of
raltegravir BID in treatment-naive and treatment-
experienced adults.20–22 Resistance testing was possible in
only a small subset of participants with PDVF; additional
resistance may have been selected in participants with
confirmed viremia but could not be detected because the
HIV-1 RNA was below the assay threshold of 500 copies
per milliliter.
The favorable safety profile of raltegravir 400 mg BID
was established in clinical trials1–4 and confirmed by post-
marketing experience.23–25 At week 96 of the ONCEMRK
trial, the QD and BID regimens continued to demonstrate
favorable safety and tolerability profiles with small increases
in the rates of drug-related adverse events after week 48
(1.5% and 1.1%, respectively), no serious drug-related
adverse events after week 48, and only 1 discontinuation
because of an adverse event after week 48. The raltegravir
1200 mg QD regimen continued to be well tolerated in
participants with chronic hepatitis (B or C) coinfection, an
important subpopulation among those with HIV-1 infection.
Treatment-emergent laboratory abnormalities were gen-
erally similar for raltegravir 1200 mg QD and raltegravir 400
mg BID. The incidence of grade 3 or 4 elevations in ALT in
the QD group (2.2%) was higher than that in the BID group
(0.8%) but was similar to rates reported in previous clinical
trials of raltegravir 400 mg BID: 1.8% in STARTMRK,20
3.4% in QDMRK,26 3% in NEAT001,27 and 2% in SPRING-
2.15 Similarly, the incidence of grade 3 or 4 elevations in AST
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in the QD group (2.1%) was higher than that in the BID group
(0.4%) but was similar to previously reported rates for
raltegravir 400 mg BID in STARTMRK (3.2%)20 and
QDMRK (3.4%).26 The incidence of grade 3 or 4 CPK
elevations (6.6% in the QD group and 4.5% in the BID group)
was similar to previously reported rates for raltegravir 400 mg
BID in QDMRK (5.4%)26 and NEAT001 (6%).27 The
transient nature of the elevations in cases without alternative
etiologies (such as viral hepatitis or hepatotoxic concomitant
therapies), the small differences between treatment groups,
and the finding that most resolved without discontinuation of
study therapy suggest that these laboratory changes do not
raise new safety concerns for raltegravir QD.
Because the ONCEMRK trial was double-blind, all
participants were required to take multiple pills BID;
therefore, the potential for improved adherence with the QD
regimen could not be evaluated in this trial. The global
distribution of the study sites and the racial diversity of the
study population support the generalizability of the study
results; however, some groups (women, older patients, and
those with hepatitis coinfection) were underrepresented.
Raltegravir 400 mg BID has shown favorable efficacy and
safety in women,28–30 hepatitis C coinfection,31 and older
patients25; additional experience with raltegravir 1200 mg QD
in these populations will help define further the safety and
efficacy profile of the new formulation. The conclusions that
can be drawn from the subgroup analyses are limited for
several reasons: some of the subgroups were small, no
adjustment was made for multiple comparisons, and the study
was not powered to detect statistically significant effects
within these subgroups.32 Nevertheless, no apparent trends
for differences in efficacy within subpopulations were noted
in this study.
In summary, the week 96 results of the ONCEMRK
trial show that the efficacy of raltegravir 1200 mg QD,
previously demonstrated at week 48, was maintained through
week 96 and was similar to the efficacy of raltegravir 400 mg
BID. Development of resistance to raltegravir remained low
(0.8%) in both treatment groups at week 96. In addition, the
overall safety profile of raltegravir 1200 mg QD continues to
be consistent with the well-established safety profile of
raltegravir 400 mg BID.
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APPENDIX 1. The ONCEMRK Study Group
ONCEMRK Primary Investigators
(by country):
Argentina: P. E. Cahn, I.Cassetti, M.Losso; Australia: M.T. Bloch, N.
Roth, J. McMahon, R. J. Moore, D. Smith; Belgium: N.Clumeck, L.
Vanderkerckhove, B.Vandercam, M.Moutschen; Canada: J.Baril, B. Con-
way, F.Smaill, G. H. R. Smith, A.Rachlis, S. L.Walmsley; Chile: C. Perez, M.
Wolff, M. F. Lasso, C. E.Chahin; Colombia: J. D. Velez, O.Sussmann;
France: J.Reynes, C.Katlama, Y.Yazdanpanah, S. Ferret, J. Durant, C.
Duvivier, I.Poizot-Martin, F.Ajana; Germany: J. K.Rockstroh, G.Faetkanhe-
uer, S.Esser, H. Jaeger, O.Degen, M. Bickel, J.Bogner, K.Arasteh, H.Hartl, A.
Stoehr; Guatemala: E. M. Rojas, E.Arathoon, L. D. Gonzalez, C. R. Mejia;
Israel: E.Shahar, D. Turner, I. Levy, Z.Sthoeger, H.Elinav; Italy: A.Gori, A.
D’ArminioMonforte, G. Di Perri, A.Lazzarin, G.Rizzardini, A.Antinori, B.
M.Celesia, F.Maggiolo; Malaysia: T. S. Chow, C. K. C. Lee, R.Iskandar
Shah Raja Azwa, M. Mustafa; Peru: M.Oyanguren, R. A. Castillo, L.Hercilla;
Phillippines: C.Echiverri; Portugal: F.Maltez, J. G.Saraiva da Cunha, I.
Neves, E.Teofilo, R.Serrao; Russia: F.Nagimova, I.Khaertynova, E.Orlova-
Morozova, E.Voronin, V.Sotnikov, A. A.Yakovlev, N. G.Zakharova, O. A.
Tsybakova; South Africa: M. E.Botes, L.Mohapi, R. Kaplan, M. S.Rassool;
Spain: J. R.Arribas, J. M.Gatell, E.Negredo, E. Ortega, J.Troya, J.Berenguer,
K.Aguirrebengoa, A.Antela; Switzerland: A.Calmy, M.Cavassini, A. Rauch,
M.Stoeckle; Taiwan: W.-H. Sheng, H. -H. Lin, H. -C. Tsai; Thailand: D.
Changpradub, A.Avihingsanon, S.Kiertiburanakul, W.R.; United Kingdom:
M. R. Nelson, A. Clarke, A.Ustianowski, A. Winston, M. A. Johnson; United
States: D. M.Asmuth, J. Cade, J. E. Gallant, P. J.Ruane, P. N. Kumar, A. E.
Luque, L. Panther, K. T.Tashima, D. Ward, D. S. Berger, C. A. Dietz, C.
Fichtenbaum, S. Gupta, K. M.Mullane, R. M. Novak, D. E. Sweet, G. E.
Crofoot, D. P.Hagins, S. T. Lewis, C. K. McDonald, E.DeJesus, L. Sloan, D.
J.Prelutsky, J. C.Rondon, S.Henn, A. J.Scarsella, J. O. Morales-Ramirez, L.
Santiago, C. D.Zorrilla, M. S.Saag, C. -B. Hsiao.
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